Drug Overview
Carisoprodol (brand name Soma) is a centrally acting skeletal muscle relaxant approved by the U.S. Food and Drug Administration to help relieve discomfort associated with acute, painful musculoskeletal conditions.
It is prescribed to alleviate muscle spasms and associated pain, often in conjunction with rest and physical therapy in adults.
Carisoprodol works by interrupting neuronal communication within the reticular formation and spinal cord, producing muscle relaxation and an increased range of motion; it is metabolized in the liver to the active compound meprobamate.
Relevant Genes and Their Roles
The primary gene involved in carisoprodol metabolism is CYP2C19, which encodes the cytochrome P450 2C19 enzyme responsible for converting carisoprodol into its active metabolite meprobamate and facilitating drug clearance.
Variations in the CYP2C19 gene can alter enzyme activity, affecting how quickly or slowly carisoprodol and its metabolite are processed; for example, certain genetic variants reduce enzyme function, leading to higher drug levels and an increased risk of adverse effects.
Impact of Genetics on Drug Response
Individuals can be classified into phenotype groups—ultrarapid, rapid, normal, intermediate, and poor metabolizers—based on CYP2C19 activity; these phenotypes influence carisoprodol exposure, with poor metabolizers having higher systemic concentrations and increased risk of sedation and central nervous system side effects, while ultrarapid and rapid metabolizers typically process the drug efficiently, similar to normal metabolizers.
Want to know what your genetics say about how you'll respond to Carisoprodol?
A Gene2Rx report reads your own DNA to show how it may affect your response to Carisoprodol and your other medications.
{# data-track routes these through the sitewide cta_click listener in
base.html, which attaches page_type / drug_name / guide_slug from the
server-resolved page context. This one file instruments the mid-article
CTA on ~114 content pages. #}
Find out today
Or see an example report first
Expected Clinical Effects of Genetic Variation
The clinical impact of CYP2C19 phenotypes on carisoprodol response can be summarized as follows:
Ultrarapid Metabolizer
- Effect on drug levels: Similar or slightly lower exposure due to faster clearance.
- Clinical consequence: Standard therapeutic response at usual doses.
- Side effects: Typical sedation and dizziness; mild to moderate, common occurrence.
Rapid Metabolizer
- Effect on drug levels: Normal exposure, with efficient metabolism.
- Clinical consequence: Standard efficacy and safety at recommended dosing.
- Side effects: Common drowsiness and headache; generally mild.
Normal Metabolizer
- Effect on drug levels: Expected exposure consistent with clinical trials.
- Clinical consequence: Usual onset of muscle relaxation and pain relief.
- Side effects: Common sedation, dizziness, and nausea; mild to moderate.
Intermediate Metabolizer
- Effect on drug levels: Slightly increased exposure due to reduced metabolism.
- Clinical consequence: Potential for enhanced sedation or prolonged effect.
- Side effects: Increased drowsiness and dizziness; mild to moderate.
Poor Metabolizer
- Effect on drug levels: Higher systemic concentrations due to slow clearance.
- Clinical consequence: Elevated risk of adverse reactions and prolonged sedation.
- Side effects: Pronounced CNS depression (excessive drowsiness, respiratory depression risk); moderate severity, less frequent.
Indeterminate/Not Available
- Effect: Unknown
- Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring.
- Side effects: As per general population; variable presentation.
Dosing Guidelines
The following dosing guidelines are based on the FDA pharmacogenetic guidance for CYP2C19 metabolism.
CYP2C19 Dosing Guideline
| Phenotype |
Clinical Consequence |
Guideline Recommendation |
| Ultrarapid Metabolizer |
No FDA guidance; exposure may be slightly lower but within normal range |
Initiate standard starting dose |
| Rapid Metabolizer |
No FDA guidance; normal metabolism expected |
Initiate standard starting dose |
| Normal Metabolizer |
No FDA guidance; normal metabolism expected |
Initiate standard starting dose |
| Intermediate Metabolizer |
No FDA guidance; slightly reduced clearance |
Initiate standard starting dose |
| Poor Metabolizer |
Higher systemic concentrations; increased risk of adverse reactions |
Consider dose reduction and monitor closely |
| Likely Intermediate Metabolizer |
Higher systemic concentrations; increased risk of adverse reactions |
Consider dose reduction and monitor closely |
| Likely Poor Metabolizer |
Higher systemic concentrations; increased risk of adverse reactions |
Consider dose reduction and monitor closely |
| Indeterminate |
Unknown impact |
Initiate standard starting dose |
| Not available |
Unknown impact |
Initiate standard starting dose |
Alternative Treatment Options
While specific pharmacogenetic alternatives for carisoprodol are not detailed in FDA guidance, clinicians may consider other centrally acting muscle relaxants such as cyclobenzaprine, methocarbamol, or baclofen based on patient tolerance and clinical judgment. These examples are for informational purposes only and are not direct recommendations.
Considering GeneSight for this medication?
Gene2Rx uses the same CPIC and FDA guidelines as GeneSight, covers more medications, costs $5-$49 instead of several hundred, and works with the 23andMe or AncestryDNA data you may already have. See the full side-by-side comparison before ordering.
Read the comparison →
Genes that affect Carisoprodol
See the full list of drugs affected by each gene:
Brand names containing Carisoprodol
See how your genetics affect each product Carisoprodol shows up in:
Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.
Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.
I'm Interested